77 results
6-K
EX-99.1
SPRC
SciSparc Ltd
30 May 23
SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP
4:01pm
Exhibit 99.1
SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP
As part … appointed a new Vice President of Strategy and Business Development, Mr. Yaki Baranes, to structure business strategies and facilitate identifying
6-K
EX-99.1
SPRC
SciSparc Ltd
19 Mar 19
Therapix Biosciences Appoints Ambassador Ron Prosor as Executive Advisor
8:04am
of cannabinoid-based treatments, announced today that the Company has appointed Ambassador Ron Prosor as a global growth strategy and international business … to the United Nations, will support Therapix to develop and execute its global growth strategy and international business development.
Ambassador Prosor’s
6-K
SPRC
SciSparc Ltd
30 May 23
SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP
4:01pm
New Strategy and Business Development VP,” a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K … Towards Unlocking Potential Value, Appoints New Strategy and Business Development VP.”
SIGNATURES
Pursuant to the requirements of the Securities
6-K
EX-99.1
SPRC
SciSparc Ltd
12 Aug 22
SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders
4:05pm
strategy."
About SciSparc (NASDAQ:SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives … forward-looking statements when it discusses its patent filing strategy and its potential to bring therapies to patients suffering with the challenges
6-K
EX-99.1
SPRC
SciSparc Ltd
31 Jul 19
Therapix Biosciences Announces Canadian Product License Issuance for TheraPEA (CannAmide™), a Non-Opiate Based Pain Management Supplement
4:03pm
genomics-based breeding techniques and development capabilities. The product license issuance for Therapix's CannAmide furthers the joint strategy … and the Company's strategy. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions
6-K
EX-99.2
z2w4dg0h5h0
22 Apr 20
Therapix Biosciences Announces Appointment of New CEO
5:30pm
6-K
0jdzs92en02keb
17 May 18
Report of Foreign Private Issuer
7:44am
6-K
EX-99.1
a85 ywhqpz
9 Jun 22
SciSparc’s Board of Directors Provides Strategic Decision
8:38am
6-K
n67tytsh gzq823it9s
14 Aug 23
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
4:31pm
6-K
EX-99.1
78undz5pcchyt34h
19 Sep 23
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
6:16pm
6-K
EX-99.1
bs33n1qc
2 Dec 20
Therapix Biosciences to Collaborate with The University of Calgary to Further Examine its Proprietary Drug Candidate THX-160 for Pain
9:25am
6-K
EX-99.3
zolvsvy
11 Apr 24
Agreement and Plan of Merger
4:05pm
6-K
dn42ne6xp1w0k7
11 Apr 24
Agreement and Plan of Merger
4:05pm
6-K
EX-99.2
lrz0g 6kb
16 Aug 21
Interim Consolidated Financial Statements
12:00am
20-F
1i6f xr8l89rtf8
1 May 17
Annual report (foreign)
12:00am
6-K
EX-99.2
12unzuc
29 Dec 22
Interim Consolidated Financial Statements
4:03pm
6-K
EX-99.1
byyjkd1x9v4rtse
16 Aug 21
Interim Consolidated Financial Statements
12:00am
6-K
EX-99.2
5i390 wub8c
9 Oct 20
Interim Consolidated Financial Statements
12:00am